Miraculins Appoints Director of Research and Development
Miraculins Inc. (TSX VENTURE: MOM), a biotechnology company dedicated to the discovery and development of diagnostic tools and therapeutic products for cancer, is pleased to announce that Stephan J. Frost, PhD, has been appointed Director, Research and Development.
“I am very pleased that Dr. Frost has accepted the offer to lead our research and development program”, said Christopher J. Moreau, President and CEO of Miraculins. “His experience with an international diagnostics company in the areas of diagnostic assay validation and development, project management and manufacturing will add significant depth to our organization.”
Previous to his appointment, Dr. Frost worked in Abbott Laboratories Diagnostics Division for over 15 years. During his tenure at Abbott, Dr. Frost was responsible for the evaluation of oncology assays available for license or acquisition from university and industry sources. Additionally, Dr. Frost was the project manager for numerous high-profile projects in the area of cancer, fertility and infectious disease diagnostics, and was responsible for the design and execution of feasibility and validation studies while supporting the manufacturing and quality control functions for the project Dr. Frost was also responsible for building and managing various dynamic teams for the achievement of development goals related to the project. Of further note, Dr. Frost developed an algorithm during his time at Abbott which demonstrates the ability to improve on the detection accuracy of a panel of lung cancer biomarkers.
Prior to joining Abbot, Dr. Frost worked as a research associate for NASA at the Johnson Space Center. Dr. Frost has a PhD in Biochemistry from the University of Texas and was awarded the Gip A. Hudson Memorial Prize for Research and the James E Beall II Memorial Scholarship. Dr. Frost had been working with Miraculins as a consultant since January 2008.
“I am looking forward to joining the Miraculins team and assuming the role of Director, Research and Development”, stated Dr. Frost. “After having reviewed Miraculins’ research as a consultant, I was very pleased to have been offered a more formalized role to lead the advancement of the Company’s diagnostics towards commercialization.”
About Miraculins Inc.
Miraculins is discovering, validating and developing biological markers (biomarkers) with clinical relevance for the diagnosis and treatment of cancers with critical unmet needs. The importance of tumor biomarkers for “common” cancers has been widely recognized and acknowledged by cancer experts and leading groups such as the National Cancer Institute and the American Cancer Society. The Company’s BEST(TM) Platform utilizes the concurrent analysis of clinical factors and biological data, and a combination of proteomic, mass spectrometric, and protein chemistry techniques for biomarker discovery.
Caution Regarding Forward-Looking Information
Certain statements contained in this press release constitute forward-looking information within the meaning of applicable Canadian provincial securities legislation (collectively, “forward-looking statements”). These forward-looking statements relate to, among other things, our objectives, goals, targets, strategies, intentions, plans, beliefs, estimates and outlook, including, without limitation, our anticipated future operating results, and can, in some cases, be identified by the use of words such as “believe,”"anticipate,”"expect,”"intend,”"plan,”"will,”"may” and other similar expressions. In addition, any statements that refer to expectations, projections or other characterizations of future events or circumstances are forward-looking statements.
These statements reflect management’s current beliefs and are based on information currently available to management. Certain material factors or assumptions are applied in making forward-looking statements, and actual results may differ materially from those expressed or implied in such statements. Important factors that could cause actual results to differ materially from these expectations include, among other things: Miraculins’ early stage of development, lack of product revenues and history of operating losses, uncertainties related to clinical trials and product development, rapid technological change, uncertainties related to forecasts, competition, potential product liability, additional financing requirements and access to capital, unproven markets, supply of raw materials, income tax matters, management of growth, partnerships for development and commercialization of technology, effects of insurers’ willingness to pay for products, system failures, dependence on key personnel, foreign currency risk, risks related to regulatory matters and risks related to intellectual property and other risks detailed from time to time in Miraculins’ filings with Canadian securities regulatory authorities, as well as Miraculins’ ability to anticipate and manage the risks associated with the foregoing. Additional information about these factors and about the material factors or assumptions underlying such forward-looking statements may be found in the body of this news release. Miraculins cautions that the foregoing list of important factors that may affect future results is not exhaustive. When relying on Miraculins’ forward-looking statements to make decisions with respect to Miraculins investors and others should carefully consider the foregoing factors and other uncertainties and potential events.
These risks and uncertainties should be considered carefully and prospective investors should not place undue reliance on the forward-looking statements. Although the forward-looking statements contained in this press release are based upon what management believes to be reasonable assumptions, Miraculins cannot provide assurance that actual results will be consistent with these forward-looking statements. Miraculins undertakes no obligation to update or revise any forward-looking statement.
The TSX Venture Exchange does not accept responsibility for the adequacy or accuracy of this release.
Contacts: Miraculins Inc. Christopher J. Moreau President and CEO (204) 477-7599 (204) 453-1546 (FAX) Email: info@miraculins.com Website: www.miraculins.com
SOURCE: Miraculins Inc.